A cancer associated fibroblast (CAF) inhibitor for use with an alternating electric field in a method of treating diseases such as cancer
Patent Information
- Application Number
- HK62026122705
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-12-29
- Filing Date
- 2026-04-29
- Publication Date
- 2026-09-11
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
The abstract discloses methods for treating subjects in need, comprising: applying an alternating electric field of a certain frequency for a certain duration to a target site of the subject in need; and administering a cancer-associated fibroblast (CAF) inhibitor to the subject in need. It also discloses methods for reducing or preventing CAF activation, comprising: applying an alternating electric field of a certain frequency for a certain duration to a cell population containing one or more fibroblasts; and contacting the cell population with a CAF activation inhibitor. Finally, it discloses methods for reducing CAF signaling, comprising: applying an alternating electric field of a certain frequency for a certain duration to a cell population containing one or more fibroblasts; and contacting the cell population with a cancer-associated fibroblast (CAF) signaling inhibitor.
Claims
CLAIMSWe claim:
1. A cancer associated fibroblast (CAF) inhibitor for use with an alternating electric field in a method of treating a subject in need thereof.
2. An alternating electric field together with a cancer associated fibroblast inhibitor for use in a method of treating a subject in need thereof.
3. The CAF inhibitor of claims 1 or the alternating electric field together with a CAF inhibitor of claim 2, wherein the target site comprises one or more cancer cells.
4. The CAF inhibitor of claims 1 or the alternating electric field together with a CAF inhibitor of claim 2, wherein the CAF inhibitor is a CAF activation inhibitor or a CAF signaling inhibitor.
5. The CAF inhibitor of claim 4 or the alternating electric field together with a CAF inhibitor of claim 4, wherein the CAF activation inhibitor is a fibroblast activation protein (FAP) inhibitor, a selective PDGFRb inhibitor, a Hsp90 inhibitor, a LRRC15 inhibitor, a selective Hedgehog inhibitor, a selective Hyaluronic acid secretion inhibitor, or an IL-1R inhibitor.
6. The CAF inhibitor of claim 5 or the alternating electric field together with a CAF inhibitor of claim 5, wherein the FAP inhibitor is Talabostat, FAP -2286, or TAM558.
7. The CAF inhibitor of claim 5 or the alternating electric field together with a CAF inhibitor of claim 5, wherein the selective PDFGRb inhibitor is sPDGFRblg, Crenolanib, Orantinib, CP-673451, SU16f, Tyrphostin AG 1296, Tyrphostin AG1433 or Seralutinib.
8. The CAF inhibitor of claim 5 or the alternating electric field together with a CAF inhibitor of claim 5, wherein the Hsp90 inhibitor is XL888, Geldanamycin, Gedunin, Tanespimycin, Luminespib, BIIV 021, CCT 018159, or 17-AAG.
9. The CAF inhibitor of claim 5 or the alternating electric field together with a CAF inhibitor of claim 5, wherein the LRRC15 inhibitor is ABBV-085 antibody.
10. The CAF inhibitor of claim 4 or the alternating electric field together with a CAF inhibitor of claim 4, wherein the CAF signaling inhibitor is a Lysyl oxidase (LOX)inhibitor, a Lysyl oxidase like (LOXL) inhibitor, CXCR4 inhibitor or CXCR12 inhibitor.
11. The CAF inhibitor of claims 1-10 or the alternating electric field together with a CAF inhibitor of claims 2-10, wherein the target site comprises one or more cancer cells.
12. The CAF inhibitor of claims 1-11 or the alternating electric field together with a CAF inhibitor of claims 2-11, wherein the CAF activation inhibitor inhibits or decreases fibroblast activation protein (FAP), alpha smooth muscle actin (aSMA), or platelet derived growth factor receptor beta (PDGFRb) expression, and / or prevents PDGFRb from interacting with or binding to PDGF, and / or prevents Hsp90 from ATPase activity that upregulates fibroblast activation.
13. The CAF inhibitor of claims 1-12 or the alternating electric field together with a CAF inhibitor of claims 2-12, wherein the frequency of the alternating electric field is between 50 kHz and 1 MHz.
14. The CAF inhibitor of claims 1-13 or the alternating electric field together with a CAF inhibitor of claims 2-13, wherein the alternating electric field has a field strength of between 0.5 and 10 V / cm RMS.
15. The CAF inhibitor of claims 1-14 or the alternating electric field together with a CAF inhibitor of claims 2-14, wherein the CAF inhibitor prevents Lox or Loxl from covalently cross-linking collagen and elastin in extracellular matrix (ECM).
